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Atrial fibrillation (AF) is the most prevalent sustained cardiac arrhythmia in adults. Catheter abla-
tion (CA) is one of the most important management strategies to reduce AF burden and AF-
associated complications. In order to stratify the risk of adverse events and to predict treatment
success in AF patients undergoing CA, several risk stratification scores had been developed dur-
ing the last decade. The aim of this review is to provide an overview of the most important clini-
cal risk scores predicting rhythm outcomes, electro-anatomical substrate and mortality in AF.
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1 | INTRODUCTION
Atrial fibrillation (AF) is the most prevalent sustained cardiac arrhyth-
mia in adults. Catheter ablation (CA) is important management strat-
egy to reduce AF burden and AF-associated complications.1 In
general, AF is associated with several cardio- and cerebrovascular
complications, such as heart failure, stroke, and death. Furthermore,
AF recurrence rates after single CA range from 30% to 50%,2 often
requiring repeated CA and leading to increased treatment costs. Path-
ophysiological, electrical, and structural atrial remodeling plays an
important role in AF pathogenesis3,4 and is associated with endothelial
damage, inflammation, and fibrosis.5 Several pro-fibrotic blood bio-
markers6,7 as well as electro-anatomical mapping during CA8 and mag-
netic resonance imaging (MRI) techniques9,10 had been shown to
predict these remodeling processes.
In order to stratify the risk of negative outcomes in AF patients
undergoing CA, several risk prediction scores had been developed.
These risk scores were established on the basis of various clinical fac-
tors, such as age, gender, body mass index (BMI), AF type, left atrial
(LA) size, heart failure, chronic kidney disease, and early AF recur-
rences (ERAF).11–18 Clinical risk scores can be categorized by their
selection of predictive factors (ie, biomarker-based or clinical variable-
based risk scores). First, there are several scores, such as CHADS2,
CHA2DS2-VASc, and R2CHADS2 that were originally developed to
predict thromboembolic events in AF patients.11–13 Later on, rhythm
Abbreviations: AF, atrial fibrillation; ANP, atrial natriuretic peptide; AUC, area
under the curve; BMI, body mass index; BNP, B-type natriuretic peptide; CA,
catheter ablation; CBA, cryoballoon ablation; EF, ejection fraction; eGFR, esti-
mated Glomerular Filtration Rate; ERAF, early recurrence of atrial fibrillation;
IDI, integrated discrimination improvement; LA, left atrium; LRAF, late recur-
rence of atrial fibrillation; LVA, low voltage area; MACE, major adverse cardiol-
ogy event; MI, myocardial infarction; MRI, magnetic resonance imaging; NRI,
net reclassification improvement; OR, odds ratio; PVI, pulmonary vein isolation;
RFA, radiofrequency ablation; ROC, receiver operating characteristics; VLRAF,
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outcome-specific prediction scores, such as ALARMEc, BASE-AF2,
APPLE, CAAP-AF, and MB-LATER, were introduced.15–20 Recently,
the prediction of mortality (2MACE)21 or electro-anatomical substrate
(DR-FLASH)22 had been investigated (Table 1). Furthermore, it had
been shown that electro-anatomical substrate measured during
CA22,23 or through MRI,9,10 was associated with arrhythmia recur-
rences after CA in AF patients.9,22 Finally, blood biomarkers had
become a promising tool for risk stratification and were included into
several risk stratification tools (eg, ABC,24–26 AEQ27).
The aim of this review is to provide an overview of the most
important clinical risk scores predicting rhythm outcomes, electro-
anatomical substrate, and mortality in AF patients undergoing CA
for AF.
2 | SEARCH STRATEGY
Comprehensive electronic searches for relevant publications were
performed in the PubMed database. For structural purposes, the liter-
ature research had been categorized according to different adverse
events considered in this article. Major search terms were generated
and combined with specific search terms for each event. The major
search terms included “atrial fibrillation OR AF” AND “score OR risk
OR index OR scheme OR ratio”. As specific search terms the following
list has been used:
1. AND “recurrence”
2. AND “LVA OR low voltage area OR substrate OR AF nest OR
atrial foci OR atrial premature depolarization (APD)”
3. AND “death OR mortality”
Studies were included when they reported the prediction of an
outcome in AF patients using risk assessment tools. Two authors (F.K.
and J.K.) screened all retrieved publications for qualifications by title
and abstract screening and full text reviewing. By applying this search
strategy, we considered a number of publications and clinical scores
to be relevant references for this article.
3 | SCORES (TABLE 1)
3.1 | CHADS2/CHA2DS2-VASc
Both scores had been originally developed for stroke prediction in AF
patients. The CHADS2 consisted of five variables: one point for con-
gestive heart failure, hypertension, age ≥ 75, diabetes mellitus, and
2 points for previous stroke.11 The scoring range is from 0 to 6 points.
The predictive value for different adverse events in AF patients was
tested in several studies. Congestive heart failure, hypertension, age ≥
75 (2 points), diabetes mellitus, previous stroke (2 points), vascular
disease, age 65 to 74 years, and female sex were included to the
CHA2DS2-VASc score.
12 The scoring range is from 0 to 9 points. TA
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3.2 | ALARMEc
The score was developed for the prediction of the arrhythmia recur-
rences after CA for AF, and ranges from 0 to 4 points19; AF clinical
type, left atrium size, renal insufficiency, metabolic syndrome, and car-
diomyopathy were considered for the ALARMEc score (1 point each).
3.3 | BASE-AF2
The BASE-AF2 score was developed to predict recurrences in AF
patients after cryoballoon ablation (CBA).15 BMI > 28 kg/m2, atrial
dilatation >40 mm, current smoking, early AF recurrence post-CA,
duration of AF history of >6 years, and non-paroxysmal type of AF
were included, each weighing 1 point.
3.4 | APPLE
The APPLE score includes age ≥ 65 years, persistent AF, impaired
eGFR (<60 mL/min/1.73 m2), LA diameter ≥ 43 mm, EF < 50%
(1 point for each variable). Therefore, a maximum of five points could
be achieved. The APPLE score can be used for the prediction of
electro-anatomical substrate and recurrences after first and repeated
CA in AF patients.16,20
3.5 | DR-FLASH
The DR-FLASH score was originally developed for the prediction of
low voltage area (LVA). The clinical variables diabetes mellitus, renal
dysfunction (assessed by using the Cockcroft-Gault formula), persis-
tent form of AF, LA diameter > 45 mm, age > 65 years, female sex
and hypertension were used in this score. Each variable scores 1 point,
so the score's range is from 0 to 7 points.22
3.6 | CAAP-AF
This score was developed to predict AF freedom after CA and ranges
from 0 to 13 points.17 Coronary artery disease, left atrial diameter,
age, presence of persistent, or long-standing AF, antiarrhythmics
failed and female sex were included to CAAP-AF score.
3.7 | MB-LATER
Male sex, bundle brunch block, left atrium ≥ 47 mm, clinical type of
AF, and early recurrent AF (ERAF) were included in the MB-LATER
score. Each variable scores 1 point. The MB-LATER score was devel-
oped to predict very late recurrences of AF (VLRAF) >12 months
after CA.18
3.8 | ATLAS
Age > 60 years (1 point), type of AF—non-paroxysmal (2 points),
indexed left atrial volume (1 point for each 10 mL/m2) female sex
(4 points) and current smoking (7 points) were detected as indepen-
dent predictors for arrhythmia recurrences after CA and they were
included in the ATLAS score.28
3.9 | ABC death risk score
Age, heart failure in the clinical history, N-terminal pro-B-type natri-
uretic peptide, troponin-T, and growth differentiation factor-15 levels
were included in the ABC death risk score.24
3.10 | 2MACE
The 2MACE scoring ranges from 0 to 7 points and it is composed of
2 points each for metabolic syndrome and age > 75 years. The
remaining variables (myocardial infarction [MI]/revascularization; con-
gestive heart failure [EF < 40%] and thromboembolic events) are
rated with 1 point each.21
3.11 | LAGO
Five clinical items had been included to the LAGO score: AF pheno-
type, structural heart disease, CHA2DS2-Vasc score < 1, LA diameter
and LA sphericity.29 Each item scores 1 point.
4 | RHYTHM OUTCOMES AFTER CATHETER
ABLATION
Arrhythmia recurrences after medical treatment (invasive or pharma-
cological) can be categorized into early recurrences (ERAF), late recur-
rences (LRAF) or very late recurrences of AF (VRLAF).11 ERAF is
defined as any atrial tachyarrhythmia occurring within 3 months after
index procedure, LRAF refers to the recurrences between 3 and
12 months post-CA, and VLRAF denotes any atrial tachyarrhythmia
recurrence, which occurs after 12 months after index procedure.
We identified eight risk assessment tools that had been applied
for prediction of arrhythmia recurrences after radiofrequency ablation
(RFA) or CBA for AF: CHADS2, ALARMEc, BASE-AF2, CAAP-AF,
APPLE, MB-LATER, ATLAS, and LAGO (Table 2).
Of note, there were substantial differences in the respective deri-
vation cohort size among the scores. Generally, the scores developed
in the large cohorts (eg, ATLAS, APPLE, and CAAP-AF) could have
better generalizability than scores derived in smaller cohorts (ie,
BASE-AF2, ALARMEc, MB-LATER), but each score would require fur-
ther validation. Although an external validation is an important quality
criterion of the risk stratification tools, it was not performed for every
score. Indeed, the ALARMEc, APPLE, and MB-LATER scores were the
only scores that had been validated in several external cohorts.
The recurrence prediction using well-known stroke risk scores (ie,
the CHADS2, CHA2DS2-VASc, and R2CHADS2 scores) has been
tested in several studies. All three scores were compared to each
other and showed only modest ability to predict the arrhythmia recur-
rence after CA for AF.30 However, CHADS2, CHA2DS2-VASc, and
R2CHADS2 were inferior compared to scores originally developed for
arrhythmia recurrence, such as the APPLE and MB-LATER scores, for
example.16,18,20,31
Of note, most of the arrhythmia outcomes-specific scores were
developed to predict the ERAF and/or LRAF after AF CA, while the
BASE-AF2 and MB-LATER scores use ERAF as a variable for the
LRAF/VLRAF prediction and, therefore, cannot be used at baseline,
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before index CA. Finally, the simplicity and practicality of a score are
very important factors for its clinical relevance. The use of clearly
defined variables, such as LA size, sex, or AF type, and easy score cal-
culation are basic necessities. Except for the ALARMEc score, which is
based on a complex calculation,32 the introduced scores are mainly
feasible.
Of note, the BASE-AF2 score had been developed in an AF cohort
undergoing CBA. The reliability of this score in the recurrence predic-
tion after RFA is not proven so far.
4.1 | CHADS2
Chao et al11 investigated the predictive value of the CHADS2 score
for arrhythmia recurrences after catheter ablation. Two-hundred
thirty-eight patients with paroxysmal AF undergoing radiofrequency
catheter ablation had been included into analysis. This study
demonstrated that LA diameter (hazard ratio [HR] 1.057, P < 0.001)
and high CHADS2 score (cut-off ≥3) (HR 1.372, P < 0.001) were inde-
pendent predictors for arrhythmia recurrence after CA which occurred
after 12 months follow-up (VLRAF).11
Several studies compared the CHADS2 and CHA2DS2-VASc
scores in terms of reccurrence prediction after CA. Letsas et al33 dem-
onstrated that the difference in receiver operating characteristics
(ROC) between CHADS2 (0.644) and CHA2DS2-VASc (0.627) did not
reach significance (P > 0.05). However, even though their study had
been based on a relatively small cohort (128 patients; median FU
16 months), both scores were able to predict recurrence after ablation
effectively. In a cohort with 2179 patients (non-paroxysmal and par-
oxysmal), Jacobs et al had demonstrated that the CHA2DS2-VASc
score is superior to the CHADS2 score regarding the prediction of
recurrence after catheter ablation.34
TABLE 2 Rhythm outcome after catheter ablation
Study Year Participants Scores Results
Chao et al 2012 Overall: 238 PAF: 238 CHADS2 A high CHADS2 score (cut-off ≥3) was an independent predictor for
arrhythmia recurrence after CA
Wójcik et al 2013 Overall: 213PAF: 99 ALARMEc ALARMEc demonstrated better predictive value than CHADS2 and
CHA2DS2-VASc scores for the prediction of arrhythmia recurrences
after repeated catheter ablation (CBA and RFA)
Canpolat et al 2013 Overall: 236 PAF: 188 BASE-AF 2 BASE-AF2 ≥ 3 points was an independent predictor for AF recurrences
after CBA (AUC = 0.94; 95% CI: 0.89-0.97, P < 0.001)
Letsas et al 2014 Overall: 128 VPAF: 128 CHADS2,
CHA2DS2-VASc
CHADS2 (AUC = 0.644) and CHA2DS2-VASc (AUC = 0.627) scores
(cut-off >2) reached moderate predictive accuracy
Wójcik et al 2014 Overall: 911 PAF: 528 ALARMEc ALARMEc score was able to predict the outcome after multiple ablation
procedures. Success
Rate after procedure was increased in patients with low ALARMEC
Kornej et al 2015 Overall: 1391 PAF: 710 APPLE APPLE demonstrated better c-indices for the prediction of LRAF after
RCAF than CHADS2 and CHA2DS2-VAS
Wójcik et al 2015 Overall: 378 PAF: 320 ALARMEc ALARMEc score could be used for the selection of patients before CBA.
In patients with ≥3 points (high risk) CBA should be avoided
Jacobs et al 2015 Overall: 2179 PAF:1246 CHADS2,
CHA2DS2-VASc
Both scores can be used for recurrence prediction after first catheter
ablation. CHA2DS2-VASc score reached slightly better results
Paylos et al 2016 Overall: 128 Only PAF ALARMEc Patients (PAF) with a low ALARMEc score had an excellent long-term
outcome after CBA (second generation)
Winkle et al 2016 Overall:2062 PAF: 644 CAAP-AF CAAP-AF score could be used for the prediction of AF freedom after
ablation. A correlation between CAAP-AF score and amount of
LA-scar (detected by magnetic resonance imaging) could be
demonstrated
Kornej et al 2017 Overall: 379 PAF: 265 APPLE APPLE score can be used for the prediction of arrhythmia recurrences
after repeated catheter ablation. The APPLE score demonstrated
better c-indices compared to CHADS2 and CHA2DS2-VASc
Mujovic et al 2017 Overall: 133 PAF: 92 MB-LATER MB-LATER achieved the highest c-index for the prediction of VLRAF
compared to APPLE, ALARMEc, BASE-AF2, CHA2DS2-VASc,
CHADS2, and HATCH
Mesquita et al 2017 Overall: 1934 AF: 1488 ATLAS ATLAS score was able to identify high-risk patients for AF-relapse after
first PVI, despite of AF type. There was n't any comparison with other
risk scores performed
Deng et al 2018 Overall: 1410 PAF: 1089 MB-LATER MB-LATER was compared to six scores (HATCH, CHADS2,
CHA2DS2-VASc, BASE-AF2, CAAP-AF, and APPLE. MB-LATER had
been reached largest net reclassification improvement
Potpara et al 2018 Overall: 226 PAF: 142 MB-LATER MB-LATER was compared with CAAP-AF, CHADS2, and
CHA2DS2-VASc. MB-LATER and CAAP-AF reached modest
predictive value for LRAF
Bisbal et al 2018 Overall: 243 PAF: 160 LAGO Different cardiovascular imaging parameters had been included to the
LAGO score. The LAGO score can be used for recurrence prediction
after RFA and CBA
Abbreviations: AF, atrial fibrillation; CBA, cryoballoon ablation; PAF, paroxysmal AF; PVI, pulmonary vein isolation; ERAF, early recurrence AF; LRAF, late
recurrence AF; VLRAF, very late recurrence AF; RFA, radiofrequency ablation.
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4.2 | ALARMEc
The ALARMEc score has been developed in a cohort of 213 patients
(73 RFA and 140 CBA patients).14 The authors reported the predictive
value of the ALARMEc score for recurrences after repeat CA in com-
parison to the CHADS2 and CHA2DS2-VASc scores. In the ROC curve
analysis, ALARMEc (area under the curve [AUC] 0.657; P < 0.001)
was superior to CHADS2 (AUC 0.533; P = 0.413) and CHA2DS2-VASc
(AUC 0.519; P = 0.641). Furthermore, the same group of authors
showed in a larger cohort of 911 patients with a longer follow-up of
60 months that patients with moderate and high ALARMEc strata
benefited from multiple procedures or more extensive substrate modi-
fication.32 Of note, there are also controversial data regarding ALAR-
MEc score showing that CBA should be avoided in patients with a
high ALARMEc score (>2 points) because they have poor outcomes.35
Interestingly, in another small study of 128 CBA patients, it was
shown that a low ALARMEc score correlated with freedom from
recurrent arrhythmia.19 Although ALARMEc is the only study addres-
sing prediction of recurrences both within 3 to 12 months and > 12
months, the results of this study are difficult to interpret because of
non-standardized definitions of renal dysfunction and metabolic syn-
drome used in that study.14,36
4.3 | BASE-AF2
The BASE-AF2 score has been developed in a cohort of 238 patients
with a follow-up of 30 months (median 20 months) after CBA. .15 A
higher BASE-AF2 score (≥3 points) was significantly associated with
AF recurrences (HR 3.34, P = 0.001). Since ERAF is used as an inde-
pendent predictor in this score, the BASE-AF2 score cannot be used
for baseline prediction, before index CA. Similar to the ALARMEc
study, some variables included in the BASE-AF2 score such as BMI
were not in accordance with current definitions.36,37 Also, the unclear
cut-off of AF duration >6 years complicates the assessment due to the
fact that in some patients AF may begin with asymptomatic episodes.
4.4 | CAAP-AF
The CAAP-AF score has been developed in a large cohort of 1125 AF
patients. Of 14 tested clinical variables, six factors (coronary artery
disease, left atrial diameter, age, presence of persistent or long-
standing AF, antiarrhythmics failed, and female sex) were significantly
associated with AF recurrence after CA. A low CAAP-AF score (<4
points) was associated with a better long-term outcome after CA,
while high CAAP-AF score (≥8 points) indicated LA scar and LVAs
which are known to increase the recurrence risk.17 The 2-year AF-free
rates by CAAP-AF score values were as follows: 0 = 100%,
1 = 95.7%, 2 = 96.3%, 3 = 83.1%, 4 = 85.5%, 5 = 79.9%, 6 = 76.1%,
7 = 63.4%, 8 = 51.1%, 9 = 53.6%, and ≥ 10 = 29.1%. The score was
internally validated in a cohort of 937 patients showing similar find-
ings as in the development cohort. Recently, the CAAP-AF score had
been externally validated and it showed a good predictive ability for
LRAF.31,38
4.5 | APPLE
The APPLE score was originally developed to predict AF recurrences
within the first year after CA.16 The development cohort consisted of
1145 AF patients undergoing first CA. The predictive value of APPLE
score was significantly superior to CHADS2 and CHA2DS2-VASc on
the ROC curve analysis (AUC 0.634 vs 0.538 and 0.542; P < 0.001,
respectively).16 Similar results (AUC 0.624, P < 0.001) were reported
in an external validation cohort of 261 patients from the Vanderbilt
University.
Moreover, the APPLE score has been shown to be useful for the
prediction of rhythm outcome after repeat CA in The Leipzig Heart
Center Ablation Registry.20 In comparison to CHADS2 (AUC 0.577,
P = 0.037) and CHA2DS2-VASc (AUC 0.590, P = 0.015), the APPLE
score showed significantly better prediction of arrhythmia recurrences
(AUC 0.617, P = 0.002) than other scores. So far, the APPLE score has
been validated in several external cohorts showing similar results as in
the development cohort. The third external validation was performed
by Mujovic et al18 comparing APPLE with the MB-LATER score. Both
scores showed reasonably good predictive ability in the ROC curve
analysis (AUC 0.716, P = 0.002 vs AUC 0.782, P < 0.001) for the pre-
diction of VLRAF.
Another comparison of the APPLE, MB-LATER, and DR-FLASH
scores has been published recently. Kornej et al39 used data from two
study groups: the BioAF cohort (Heart Center Leipzig), which con-
sisted of 241 patients, and The Leipzig Heart Center AF Ablation
Registry, which provided 873 patients for the validation cohort.
Beside LVA prediction, the predictive value for LRAF had been ana-
lyzed. The APPLE score (OR 1.550; P < 0.001) was significantly asso-
ciated with arrhythmia recurrence within 1 year after CA in the
validation cohort. Of note, on multivariable analysis only the MB-
LATER score (OR 1.747; P < 0.001) achieved slightly higher values
within the validation cohort.39
4.6 | MB-LATER
The MB-LATER score has been introduced to predict VLRAF after
RFA in 133 patients who were free from recurrent arrhythmia within
first 12 months after CA.18 After the development and internal valida-
tion (cohort of 39 patients), the score was compared to APPLE (AUC
0.716); BASE-AF2 (AUC 0.648), ALARMEc (AUC 0.671), HATCH (AUC
0.582), CHADS2 (AUC 0.555), and CHA2DS2-VASC (AUC 0.510)
scores.18 According to this comparison, MB-LATER showed better
predictive accuracy for VLRAF (AUC 0.782, P < 0.001) than the other
scores. Of note, the APPLE score (AUC 0.716, P = 0.002) showed
almost similar prediction as the MB-LATER score.18
Recently, two external MB-LATER score validation studies have
been published. First, Deng et al used a Chinese cohort of >1400
patients.31 They compared seven risk stratification scores (HATCH,
CHADS2, CHA2DS2-VASc, BASE-AF2, APPLE, CAAP-AF, MB-LATER)
regarding their predictive ability for LRAF after CA. The MB-LATER,
APPLE, BASE-AF2, and CAAP-AF reached good predictive values with
an AUC of 0.73, 0.74, 0.75, and 0.71, respectively (all P < 0.01). These
scores were superior to HATCH (AUC 0.58, P < 0.01), CHADS2 (AUC
0.57, P < 0.01), and CHA2DS2-VASc (AUC 0.57, P < 0.01). However,
324 KOSICH ET AL.
the MB-LATER score had the largest net reclassification index (NRI,
for 30%-82.6%) and integrated discrimination index (IDI, for 2.6%-
18.6%) in comparison to other scores.
Of note, APPLE score had been mentioned as an alternative to
MB-LATER.31 It is noteworthy that a score value of ≥2 of both MB-
LATER (HR 1.52,P < 0.01) and APPLE score (HR 1.35, P < 0.01) has
been significantly associated with an increased risk (52.1% and 35.3%,
respectively) for AF recurrences.31 The second external validation
study had been performed by Potpara et al38 in a cohort of
226 patients. The MB-LATER score was compared to CHADS2,
CHA2DS2-VASc, and CAAP-AF scores regarding their predictive abil-
ity for LRAF. Only MB-LATER (AUC 0.62, P = 0.003) and CAAP-AF
(0.59, P = 0.024) significantly predicted arrhythmia recurrences, and
MB-LATER showed the largest net benefit compared to the other
scores38 In ROC analysis. In addition, also as shown in Dengs study,
the MB-LATER cut-off value of ≥2 had reached the highest predictive
ability for LRAF. In both external validation cohorts ERAF, which has
been included in the MB-LATER score, was shown to be an indepen-
dent predictor for LRAF, which may partly explain the good predictive
values of the MB-LATER. Interestingly, MB-LATER included male sex
as a risk factor for recurrences in contrast to the CAAP-AF17 and
ATLAS28 scores which included female sex as a risk factor. The MB-
LATER score good predictive ability for VLRAF could be partly
explained by higher AF prevalence in men.40,41
4.7 | ATLAS
The ATLAS score has been developed in a cohort of 1934 AF patients
undergoing first CA which were divided into a development and a vali-
dation cohort (50% each).28 ATLAS score classified patients into low
(<6 points), intermediate (6-10 points) and high risk (>10 points) for
arrhythmia recurrences. Patients were followed-up for 4.2 ± 2.7 years,
and recurrent arrhythmia occurred in 22% of patients during follow-
up. In the development group, AF recurrence rates were 8, 11, and
17%/year for low (<6 points), intermediate (6-10 points) and high-risk
patients (>10 points), respectively (P < 0.001). In the validation group,
AF recurrence rates were 8, 11, and 18%/year, respectively
(P < 0.001). There were significant differences in hazard ratio
(HR) between intermediate (1.10, P = 0.35) and high (1.6, P < 0.001)
risk groups. The score showed good discriminative power (censored c-
statistic of 0.75 in both cohorts). Comparisons among other risk strati-
fication scores were not performed.28
4.8 | LAGO
Different cardiovascular imaging parameters, such as LA sphericity
had been shown to be associated with AF. Based on this knowledge,
Bisbal et al29 developed the left atrial geometry and outcome (LAGO)
score in a multicenter study including 243 patients after first RFA or
CBA. So far, the score is not validated in a larger cohort, further inves-
tigations are needed. Furthermore, the study cohort includes both
RFA and CBA, the predictive value of the LAGO score for each abla-
tion technique in particular is not shown.29
5 | PREDICTION OF LOW-VOLTAGE
AREA/ELECTRO-ANATOMICAL SUBSTRATE
AF progression is related to electro-anatomical changes in atrial myo-
cardium and indicates advanced atrial remodeling. LVA can be
detected during CA and through MRI,9and was defined as any region
with <0.5 mV23 during electro-anatomical voltage mapping. Voltage-
guided substrate modification by targeting LVA in addition to circum-
ferential pulmonary vein isolation (PVI) is more effective than conven-
tional PVI ablation approaches concerning arrhythmia freedom after
the ablation.42–44 Recently, Yagishita et al showed that an LA voltage
cut-off of <1.1 mV for electro-anatomic voltage mapping in sinus
rhythm was an independent predictor for recurrences in patients
without LVA (<0.5 mV).45 Although LVA is an important risk factor for
post-procedural AF, there are no standardized methods to predict
LVA non-invasively before CA.43,44
The predictive ability of CHADS2, DR-FLASH, APPLE, and MB-
LATER for LVA are discussed in this section (Table 3).
5.1 | CHADS2
Chao et al demonstrated that electrophysiological properties of the
atrium differ between CHADS2 strata, in a cohort of 247 patients with
paroxysmal AF. In this study, the authors compared atrial voltage and
total activation time of right and left atrium within CHADS2 strata.
46
In this relatively small cohort, it could be demonstrated that a higher
CHADS2 score (>3 pts.) is associated with LVA.
5.2 | DR-FLASH
The DR-FLASH score is currently the only score developed specifically
for the prediction of LVA. The derivation cohort included 238 patients
(153 with persistent AF). LVAs were found in 66 (28%) patients, and
the score showed a good predictive ability for LVA with cut-off of
3 points (c-statistic 0.801; P < 0.001). The DR-FLASH score has been
validated in an external cohort and showed similar results (AUC was
0.767, P < 0.001). Furthermore, DR-FLASH showed also a predictive
ability for AF recurrence (1.3-fold increase per 1 point, P = 0.020)
post-CA. Patients with LRAF had also a high DR-FLASH score (cut-off
>3).22 Of note, female sex—as a component of DR-FLASH score —was
recently considered as a risk factor for AF substrate. Indeed, females
have a 2-fold risk for LVA47 and an almost 3-fold increased risk for AF
recurrence following CA.4 Females could present with clinical AF in a
later stage of fibro-fatty infiltration, which could explain a higher pres-
ence of electro-anatomical substrate and worse rhythm outcomes
after CA in female patients.47
5.3 | APPLE
Recently, it has been shown that the APPLE score—originally devel-
oped for arrhythmia recurrences—could be also used to predict
LVA.39 In a population of 214 patients, we showed that the APPLE
score (OR 1.921, P < 0.001) and female sex (OR 2.283, P = 0.005)
were independent predictors for LVA .39 Interestingly, although atrial
natriuretic peptide (NT-proANP) was an independent predictor on
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univariable analysis, there was no increase in the predictive value by
adding NT-proANP to the APPLE score. Importantly, the APPLE score
can be used for baseline prediction of recurrent AF post-CA and con-
tribute to an individualized AF therapy. Its components such as an
impaired ejection fraction (EF) and renal dysfunction were also associ-
ated with an electro-anatomical substrate.48,49
This correlation had also been shown in our recent study where
the APPLE, DR-FLASH, and MB-LATER scores were compared
regarding their predictive ability for LVA and recurrences.50 First, we
analyzed this prediction in the BioAF cohort of 214 AF patients and
then validated the results in a retrospective cohort from The Leipzig
Heart Center AF Ablation Registry. While on univariable analysis all
scores were significantly associated with LVA, on multivariable analy-
sis only the APPLE (OR 1.789, P < 0.001) and DR-FLASH scores
(OR 2.144, P < 0.001) remained significant predictors. However, the
MB-LATER score (OR 1.445, P = 0.034) and ERAF (OR 5.078,
P < 0.001), but not the APPLE score, were associated with LRAF on
multivariable analysis.50 All scores were significantly associated with
recurrences, but ERAF was the most powerful predictor for later
rhythm outcomes. In summary, on multivariable analysis the APPLE
score was associated with prediction of both LVA and arrhythmia
recurrences, whereas, as expected, DR-FLASH score (“a substrate
score”) showed the best prediction for LVA, but not for rhythm out-
comes, and MB-LATER was significantly associated with rhythm out-
comes, but not LVA.
6 | MACE AND DEATH
Several studies demonstrated that AF is associated with an increased
risk of stroke, heart failure, or sudden cardiac death.51,52 Conse-
quently, AF patients have a higher mortality rate compared to patients
without AF regardless of gender and age.51,53 In addition, it had been
demonstrated that an increased mortality rate in anticoagulated AF
patients is mostly because of cardiovascular causes other than ische-
mic stroke.54,55
In this section, the CHADS2/CHA2DS2-VASc, ABC death risk
score and the 2MACE score (Table 4) are discussed in terms of their
relevance for death or major adverse cardiovascular events (MACE)
prediction including fatal/non-fatal myocardial infarction, cardiac
revascularization, and cardiovascular death.
6.1 | CHADS2/CHA2DS2-VASc
The value of CHA2DS2-VASc and CHADS2 score for death and stroke
prediction in AF patients after catheter ablation had been investigated
by Chao et al52 Both scores had been compared in a cohort of 565 AF
patients. CHA2DS2-VASc score had been shown slightly better results
(AUC 0.830) than the CHADS2 score (AUC 0.785) in ROC analysis.
However, the difference between both curves did not reach signifi-
cance (P = 0.116).52 Both scores had been proven their ability to pre-
dict death and thromboembolic events in AF patients after CA. Similar
findings had been published by Jacobs et al34 in 2015. The predictive
ability of CHA2DS2-VASc and CHADS2 score for death and MACE
after first CA had been investigated in a cohort of 2179 AF patients.
After FU of 5 years, it had been shown that CHA2DS2-VASc (HR 1.16;
P = 0.04) and CHADS2 (HR 1.30; P = 0.02) score were associated
with MACE.
6.2 | 2MACE
The 2MACE score includes five clinical variables, and it has been
developed for the prediction of major adverse cardiovascular events
(MACE) in a derivation cohort of 1019 AF patients with oral
TABLE 3 Low voltage area (LVA)/electro-anatomical substrate
Study Year Participants Scores Results
Chao et al 2011 Overall: 247 PAF: 247 CHADS2 Higher CHADS2-score is associated with LVA prediction
Kosiuk et al 2015 Overall: 902 PAF: 545 DR-FLASH The optimal cut-off value for LVA prediction was 3 points.
DR-FLASH score was also associated with the prediction of
arrhythmia recurrences after PVI
Kornej et al 2018 Overall: 214 PAF: 88 APPLE APPLE score and NT-proANP were independent predictors for
LVA before catheter ablation
Kornej et al 2018 Overall:1114 PAF: 621 APPLE, DR-FLASH,
MB-LATER
APPLE and DR-FLASH demonstrated robust predictive value
for LVA in both study groups
Abbreviations: AF, atrial fibrillation; PAF, paroxysmal AF; PVI, pulmonary vein isolation.
TABLE 4 MACE and death
Study Year Participants Scores Results
Jacobs et al 2015 Overall: 2179 PAF:1246 CHADS2, CHA2D
S2- VASc
Both scores were associated with MACE prediction after
catheter ablation (FU 5 years) CHA2DS2-VASc (HR 1.16;
P = 0.04) and CHADS2 (HR 1.30; P = 0.02)
Pastori et.al 2016 Overall: 2108 et al PAF:n.a. 2MACE The highest specificity and sensitivity for MACE could be
reached by an value of three in the 2MACE score
Hijazi et al 2017 Overall: 23159 PAF:4115 ABC death score ABC death score was compared to CHA2DS2-VASc score and
it achieved higher c-indices. Three biomarkers (growth
differentiation factor 15, high sensitivity cardiac troponin T
and N-terminal pro B-type natriuretic peptide) were used in
the ABC death score
Abbreviations: AF, atrial fibrillation; PAF, paroxysmal AF; MACE, major adverse cardiovascular events.
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anticoagulation (OAK). The median follow-up was 24 months (IQR
13.9-46.3) or 2287 person-years. The MACE incidence rate was
3.4%/year (111 cases). The external validation cohort included 1089
AF patients who were treated with vitamin K antagonists. The cut-off
value of 3 points in the 2MACE score showed the best combination
of sensitivity and specificity to predict MACE, and the score (AUC
0.79; P < 0.001) was superior to CHADS2 (AUC 0.660) and CHA2DS2-
VASc (AUC 0.667). In an external validation cohort, the predictive abil-
ity of 2MACE score has been confirmed (AUC 0.66, P < 0.001).21
Indeed, all three investigated scores (ie, the CHADS2, CHA2DS2-VASc,
and 2MACE) showed similar ability for the prediction of MACE. In
addition, it was shown that an optimal anticoagulation level also
reduced the risk of MACE.21
While number of participants within the study groups was rela-
tively large, the incidence of MACE was only ~ 180 out of 1.019
patients. Therefore, the predictive value of the 2MACE score needs to
be validated in further studies.
6.3 | ABC death risk score
Recently, the ABC death risk score had been introduced to predict
death in AF patients without CA treatment.24 The development
(ARISTOTLE) and external validation (RE-LY trial) cohorts included
over 23 000 patients. The average follow-up in derivation cohort was
1.9 years or 28 396 person-years. The external validation cohort was
based on 16 794 person-years of follow-up. The incidence rate of car-
diovascular death was 3.69 per 100 person-years (1047 events) in the
development cohort and 3.54 per 100 person-years (594 events) in
the external validation cohort.
The ABC score was compared to CHA2DS2-VASc score in both
cohorts and different subgroups. The ABC score showed a better pre-
dictive ability for mortality risk (AUC 0.75) than CHA2DS2-VASc (AUC
0.58) in all cohorts and subgroups.
Presently, these are the largest analyses using blood biomarkers
(ie, cardiac troponin T, growth differentiation factor-15, and NT-
proBNP) in AF patients. The usefulness of biomarkers as an important
tool for risk prediction was also shown in several other studies.7,56–59
AF causes endothelial damage, inflammation, and fibrosis,5 and such
atrial remodeling can be detected by specific biomarkers.58 Further-
more, the predictive value of biomarkers of inflammation (CRP, IL-
6),60 myocardial damage (troponin), impaired cardiac function (BNP,
ANP) or renal dysfunction (cystatin C) for adverse events in AF
patients has been increasingly reported.58 Natriuretic peptides, which
were used in the ABC risk score, showed a good predictive ability for
adverse events in AF patients,60–62 whereas the results for Galectin
3 were conflicting.56,57,63,64
The role of biomarkers in AF treatment decision-making in daily
clinical practice needs to be further elucidated.
7 | CONCLUSION AND FUTURE
DIRECTIONS
The major purpose of this review article was to provide an overview
of the current scores for diverse negative events in AF patients under-
going catheter ablation and to discuss them critically. The develop-
ment of the “ideal score” for prediction negative outcomes in AF
patients still remains a clinical unmet need. Therefore, choosing only
one optimal scoring system seems impossible, regarding that all of the
presented scores in this review have their strengths and limitations.
We therefore recommend to consider several important quality crite-
rions for risk stratification scores: (a) size of development cohort,
(b) an external validation, (c) clinical relevance, and (d) simplicity and
practicality of each score. Moreover, the possibility of baseline predic-
tion upfront the catheter ablation plays an important role due to a
better feasibility (Table 5).
However, there are several scores useful for the prediction of at
least one adverse outcome. While DR-FLASH and APPLE scores are
useful for prediction of both LVA and recurrences, the MB-LATER and
APPLE scores predict recurrences within first year after ablation as well
as >12 months (very late outcomes). Nevertheless, further investiga-
tions are needed to develop a universal score for patients undergoing
AF catheter ablation. Biomarkers as well as cardiovascular imaging
could improve the existing scores leading to better predictive values.
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